AKT1 and breast cancer: Network pharmacology analysis demonstrated that significant amount of “drug-disease” common targets were involved in PI3K-AKT pathway; phenylacetic acid, dodec-9-ynyl ester and 2-Pyrazoline-3-carboxylic acid, 5-hydroxy-1-(4-methylbenzoyl)-5-phenyl-, methyl ester from LEO directly interacted with AKT1 and PIK3CA; western blotting results further confirmed the decrease in AKT1 level and increase in PIK3CA level after treatment with LEO in both breast cancer cell lines.